FUJIFILM Holdings Corporation (4901.T)
| Previous close | 3,369.00 |
| Open | 3,371.00 |
| Bid | 3,409.00 x 0 |
| Ask | 3,414.00 x 0 |
| Day's range | 3,354.00 - 3,418.00 |
| 52-week range | 2,368.33 - 3,515.00 |
| Volume | |
| Avg. volume | 4,279,455 |
| Market cap | 4.109T |
| Beta (5Y monthly) | 0.22 |
| PE ratio (TTM) | 17.18 |
| EPS (TTM) | 198.64 |
| Earnings date | 09 May 2024 |
| Forward dividend & yield | 46.67 (1.37%) |
| Ex-dividend date | 28 Mar 2024 |
| 1y target est | 3,805.50 |
Globe NewswireFujifilm Healthcare Europe launches lifelike ESD training simulator EndoGel
RATINGEN, Germany, April 19, 2024 (GLOBE NEWSWIRE) -- FUJIFILM Healthcare Europe GmbH is pleased to announce the launch of EndoGel, a training model designed for performing Endoscopic Submucosal Dissection (ESD) and Peroral Endoscopic Myotomy (POEM) procedures. This innovative simulator, available in two versions - EndoGel for ESD and EndoGel for ESD/POEM - represents a significant advance in endoscopic training. This simulator aims to improve the skills of endoscopy professionals across Europe
- Business Live
More than 120 jobs at risk as major North East employer launches restructure
A total of 126 jobs are potentially set to go at the three North-east Fujifilm Diosynth Biotechnologies UK sites
Globe NewswireFujifilm Healthcare Europe partners with R Zero to bring next-gen training simulation technology to European endoscopists
mikoto Colonoscopy training simulator by R ZERO Inc. This portable training simulator offers multiple polyps, a realistic colon texture, four levels of difficulty and the recording of multiple procedure metrics. RATINGEN, Germany, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Fujifilm Healthcare Europe GmbH has announced a strategic partnership with R Zero for the exclusive distribution of mikoto, a state-of-the-art endoscopy simulation technology, throughout Europe. This collaboration aims at providing tra
